Hengerer, Fritz H.
Auffarth, Gerd U.
Conrad-Hengerer, Ina
Article History
Received: 17 October 2023
Accepted: 17 January 2024
First Online: 16 February 2024
Declarations
:
: Fritz Hengerer: Research grant and lecture fees from Glaukos Corp (unrelated to study/publication). Ina Conrad-Hengerer: No disclosures. Gerd U. Auffarth: (1 = Research Grants; 2 = Travel Expenses; 3 = Lecture Fees; 4 = Consulting). Acufocus3. Alcon (1, 2, 3, 4). AMO/Johnson&Johnson (1,2,3,4). Biotech (1,3). Carl Zeiss Meditec (1,2,3,4). Contamac (1). Cristalens (1,3,4). Croma (1). Eyebright (3). EyeYon (1,2,4). Hanita (1). Hoya (1,2,3). Kowa (1,2,3). Teleon (1,2,3). Oculus (1,3). Physiol (1). Presbia (4). Rayner (1,2,3,4). Rheacell (1). SIFI (1,2,3,4). Ursapharmc (1,2,3). VSY (1,3,4).
: All procedures performed were in accordance with the ethical standards of the institutional and/or national research committee (the Institutional Review Board of the University of Heidelberg [reference #S-482/2012]), and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.